Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25664840 | 1.00 | PLA2G1B (0.33) | PLA2G1BPLA2G2A | |
| SCHEMBL5948426 | 0.93 | PLA2G1B (0.32) | PLA2G1BPLA2G2A | |
| SCHEMBL20374734 | 0.90 | TSHR (0.31) | — | |
| SCHEMBL12059271 | 0.90 | TSHR (0.31) | — | |
| SCHEMBL5948706 | 0.87 | SIGMAR1 (0.34) | PLA2G1BPLA2G2A | |
| SCHEMBL13819759 | 0.87 | SIGMAR1 (0.34) | PLA2G1BPLA2G2A | |
| SCHEMBL12059203 | 0.86 | PLA2G1B (0.39) | PLA2G1BPLA2G2A | |
| SCHEMBL24278655 | 0.82 | PLA2G1B (0.39) | PLA2G1BPLA2G2A | |
| SCHEMBL22549218 | 0.82 | CYP1A2 (0.37) | — | |
| SCHEMBL24495074 | 0.82 | PLA2G1B (0.31) | PLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| WO-2022135432-A1 | MACROCYCLIC HETEROCYCLIC COMPOUNDS AS EGFR INHIBITORS, AND USE THEREOF | 南京圣和药业股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022120207-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | PLA2G1B 1770/4885PLA2G2A 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.